FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018786235> ?p ?o ?g. }

• W2018786235 endingPage "765" @default.
• W2018786235 startingPage "763" @default.
• W2018786235 abstract "IN 1999, I HAD the tremendous good fortune to be invited to investigate a developing medical mystery. My academic mentor, Dr Philip Leboit, during a period of several years, had identified several patients with an as-yet undescribed skin disorder. A preliminary announcement and description was published,1Cowper S.E. Robin H.S. Steinberg S.M. Su L.D. Gupta S. LeBoit P.E. Scleromyxoedema-like cutaneous disease in renal-dialysis patients.Lancet. 2000; 356: 1000-1001Abstract Full Text Full Text PDF PubMed Scopus (790) Google Scholar and a detailed examination of the clinical and histological characteristics of this disorder was published 1 year later.2Cowper S.E. Su L. Robin H. Bhawan J. LeBoit P.E. Nephrogenic fibrosing dermopathy.Am J Dermatopathol. 2001; 23: 383-393Crossref PubMed Scopus (426) Google Scholar I was quite excited to be afforded the opportunity to name a new disease; after several alternatives were discussed and modified, Dr Leboit and I dubbed the newcomer “nephrogenic fibrosing dermopathy” (NFD). At the time, NFD fairly well encapsulated what we knew of the disorder. The original details derived from the small sampling of patients in the initial study set remain essentially intact to this day. NFD was (and still is) a scleroderma-like disease of the skin that affects only patients with renal insufficiency. The clinical and histological findings are sufficiently unique to enable confident diagnosis in most cases.2Cowper S.E. Su L. Robin H. Bhawan J. LeBoit P.E. Nephrogenic fibrosing dermopathy.Am J Dermatopathol. 2001; 23: 383-393Crossref PubMed Scopus (426) Google Scholar The dermopathy of NFD was “nephrogenic” in that renal dysfunction was (and still is) a prerequisite for all cases of NFD.3Cowper S.E. Nephrogenic fibrosing dermopathy The first six years.Curr Opin Rheumatol. 2003; 15: 785-790Crossref PubMed Scopus (243) Google Scholar The concept that renal function is tied to disease activity was reinforced by several additional observations: (1) a small number of patients with acute renal failure (of any cause) developed NFD within 2 to 4 weeks after the onset of renal dysfunction2Cowper S.E. Su L. Robin H. Bhawan J. LeBoit P.E. Nephrogenic fibrosing dermopathy.Am J Dermatopathol. 2001; 23: 383-393Crossref PubMed Scopus (426) Google Scholar, 4Evenepoel P. Zeegers M. Segaert S. et al.Nephrogenic fibrosing dermopathy A novel disabling disorder in patients with renal failure.Nephrol Dial Transplant. 2004; 19: 469-473Crossref PubMed Scopus (75) Google Scholar; (2) for the lucky few for whom renal failure could be restored, NFD generally improved and/or resolved without any skin-directed therapy2Cowper S.E. Su L. Robin H. Bhawan J. LeBoit P.E. Nephrogenic fibrosing dermopathy.Am J Dermatopathol. 2001; 23: 383-393Crossref PubMed Scopus (426) Google Scholar, 5Jan F. Segal J.M. Dyer J. Leboit P. Siegfried E. Frieden I.J. Nephrogenic fibrosing dermopathy Two pediatric cases.J Pediatr. 2003; 143: 678-681Abstract Full Text Full Text PDF PubMed Scopus (82) Google Scholar, 6Mackay-Wiggan J.M. Cohen D.J. Hardy M.A. Knobler E.H. Grossman M.E. Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease).J Am Acad Dermatol. 2003; 48: 55-60Abstract Full Text Full Text PDF PubMed Scopus (168) Google Scholar, 7Swartz R.D. Crofford L.J. Phan S.H. Ike R.W. Su L.D. Nephrogenic fibrosing dermopathy A novel cutaneous fibrosing disorder in patients with renal failure.Am J Med. 2003; 114: 563-572Abstract Full Text Full Text PDF PubMed Scopus (188) Google Scholar; and (3) case reports and anecdotal evidence suggest that restoration of renal function by means of early transplantation improves and/or resolves NFD.5Jan F. Segal J.M. Dyer J. Leboit P. Siegfried E. Frieden I.J. Nephrogenic fibrosing dermopathy Two pediatric cases.J Pediatr. 2003; 143: 678-681Abstract Full Text Full Text PDF PubMed Scopus (82) Google Scholar To this day, all cases of NFD reported to the NFD Registry at Yale University8Cowper SE: Nephrogenic Fibrosing Dermopathy [NFD/NSF Web site], 2001-2005. Available at: http://www.icnfdr.org. Accessed: July 28, 2005Google Scholar have had some element of renal dysfunction at the time of disease onset. In 1997 and 1998, as the first cases were uncovered in a renal transplantation center in southern California, the natural assumption was that transplantation (or the drugs administered after transplantation) might be to blame.9Leboit P.E. What nephrogenic fibrosing dermopathy might be.Arch Dermatol. 2003; 139: 928-930Crossref PubMed Scopus (100) Google Scholar As additional cases were identified (many in nontransplantation patients), attention shifted to dialysis. However, the findings could not be explained by any single dialysis regimen, and this explanation failed to incorporate the 10% of subsequent patients reported to the registry (and elsewhere) who had never been dialyzed at the time of NFD onset.2Cowper S.E. Su L. Robin H. Bhawan J. LeBoit P.E. Nephrogenic fibrosing dermopathy.Am J Dermatopathol. 2001; 23: 383-393Crossref PubMed Scopus (426) Google Scholar, 6Mackay-Wiggan J.M. Cohen D.J. Hardy M.A. Knobler E.H. Grossman M.E. Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease).J Am Acad Dermatol. 2003; 48: 55-60Abstract Full Text Full Text PDF PubMed Scopus (168) Google Scholar, 7Swartz R.D. Crofford L.J. Phan S.H. Ike R.W. Su L.D. Nephrogenic fibrosing dermopathy A novel cutaneous fibrosing disorder in patients with renal failure.Am J Med. 2003; 114: 563-572Abstract Full Text Full Text PDF PubMed Scopus (188) Google Scholar, 8Cowper SE: Nephrogenic Fibrosing Dermopathy [NFD/NSF Web site], 2001-2005. Available at: http://www.icnfdr.org. Accessed: July 28, 2005Google Scholar, 10Obermoser G. Emberger M. Wieser M. Zelger B. Nephrogenic fibrosing dermopathy in two patients with systemic lupus erythematosus.Lupus. 2004; 13: 609-612Crossref PubMed Scopus (24) Google Scholar A broader search for a common denominator resulted in the notion that—without exception—all patients with NFD have renal dysfunction. The search for more common denominators was on. With help from the Centers for Disease Control and Prevention,11Centers for Disease Control and Prevention (CDC) Fibrosing skin condition among patients with renal disease—United States and Europe, 1997-2002.MMWR Morb Mortal Wkly Rep. 2002; 51: 25-26PubMed Google Scholar a systematic investigation of the first cases of NFD in California suggested that no single medication or infectious agent was to blame. Epidemiological information from the registry indicates no sex or race predilection is present. Reports of isolated cases of NFD in Asia and Europe4Evenepoel P. Zeegers M. Segaert S. et al.Nephrogenic fibrosing dermopathy A novel disabling disorder in patients with renal failure.Nephrol Dial Transplant. 2004; 19: 469-473Crossref PubMed Scopus (75) Google Scholar, 12Dawn G. Holmes S.C. Scleromyxoedema-like eruption following haemodialysis or nephrogenic fibrosing dermopathy?.Br J Dermatol. 2004; 150 (letter): 167-168Crossref PubMed Scopus (7) Google Scholar, 13Lauchli S. Zortea-Caflisch C. Nestle F.O. Burg G. Kempf W. Nephrogenic fibrosing dermopathy treated with extracorporeal photopheresis.Dermatology. 2004; 208: 278-280Crossref PubMed Scopus (81) Google Scholar, 14Tan A.W. Tan S.H. Lian T.Y. Ng S.K. A case of nephrogenic fibrosing dermopathy.Ann Acad Med Singapore. 2004; 33: 527-529PubMed Google Scholar indicate that this is not a phenomenon unique to the United States. In 2003, several lines of evidence came together to lend strong support to the notion that NFD is a systemic illness. One observation was the identification of an immunologically unique cell in the biopsy material of many people with NFD: the circulating fibrocyte.15Cowper S.E. Bucala R. Nephrogenic fibrosing dermopathy Suspect identified, motive unclear.Am J Dermatopathol. 2003; 25 (letter): 358Crossref PubMed Scopus (151) Google Scholar The circulating fibrocyte is a relatively recently described bone marrow–derived leukocyte that is unique in its coexpression of leukocyte markers, markers of antigen presentation, and collagen I. This cell has been cultured in the laboratory, and its growth characteristics have been studied extensively. The circulating fibrocyte has been implicated in several disease processes and appears to be the major constituent in the cutaneous biopsy samples of most patients with NFD.16Quan T.E. Cowper S. Wu S.P. Bockenstedt L.K. Bucala R. Circulating fibrocytes Collagen-secreting cells of the peripheral blood.Int J Biochem Cell Biol. 2004; 36: 598-606Crossref PubMed Scopus (490) Google Scholar A second line of evidence, developed in 2003, was the first reported autopsy of a patient with NFD.17Ting W.W. Stone M.S. Madison K.C. Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement.Arch Dermatol. 2003; 139: 903-906Crossref PubMed Scopus (258) Google Scholar This, and several subsequent reports (including several cases investigated by the registry project, but not yet published), establish without question that NFD is a systemic disease. In this issue of the American Journal of Kidney Diseases, Daram et al18Daram S.R. Cortese C.M. Bastani B. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis Report of a new case with literature review.Am J Kidney Dis. 2005; 46: 754-759Abstract Full Text Full Text PDF PubMed Scopus (140) Google Scholar reinforce the concepts that have evolved during the past 8 years regarding NFD. Their work, along with the work of others, has argued successfully for an evolutionary step in the nomenclature of NFD. Approximately 1 year ago, on the basis of published reports and the volume of data available in the registry, the terminology of NFD was modified to reflect an updated understanding of the disease process: nephrogenic systemic fibrosis (NSF). To many readers of this journal, NFD/NSF is a mysterious orphan disease that likely will never cross the office threshold. In the hopes of dispelling this notion, I share some observations drawn from my own experience. First, before 1997, this disorder did not exist. It is highly likely that a new agent or a technique (as yet unverified) is causing NFD/NSF.2Cowper S.E. Su L. Robin H. Bhawan J. LeBoit P.E. Nephrogenic fibrosing dermopathy.Am J Dermatopathol. 2001; 23: 383-393Crossref PubMed Scopus (426) Google Scholar, 3Cowper S.E. Nephrogenic fibrosing dermopathy The first six years.Curr Opin Rheumatol. 2003; 15: 785-790Crossref PubMed Scopus (243) Google Scholar, 9Leboit P.E. What nephrogenic fibrosing dermopathy might be.Arch Dermatol. 2003; 139: 928-930Crossref PubMed Scopus (100) Google Scholar Until we identify this agent, more cases undoubtedly will develop. Second, this disease is devastating. I have encountered patients who, misunderstanding that dialysis might be causing their NFD/NSF, chose to voluntarily terminate dialysis therapy. Many patients progress from ambulation to wheel-chair dependency within a few weeks. Some patients experience intractable pain. Third, after clinicians have diagnosed NFD, they frequently find other cases—suggesting many cases are going unrecognized because of lack of familiarity. NFD/NSF causes long-term morbidity and occasional mortality. Initial impressions suggest early and aggressive intervention is justified. Although several therapies have shown promise,3Cowper S.E. Nephrogenic fibrosing dermopathy The first six years.Curr Opin Rheumatol. 2003; 15: 785-790Crossref PubMed Scopus (243) Google Scholar, 13Lauchli S. Zortea-Caflisch C. Nestle F.O. Burg G. Kempf W. Nephrogenic fibrosing dermopathy treated with extracorporeal photopheresis.Dermatology. 2004; 208: 278-280Crossref PubMed Scopus (81) Google Scholar no therapy has been as effective as restoration of renal function. Many of these patients are already awaiting renal transplantation. For those who are eligible, it would be most judicious to proceed with transplantation as soon as it can be arranged. Because many patients with NFD/NSF harbor an underlying thrombotic tendency (as illustrated in the case report of Daram et al18Daram S.R. Cortese C.M. Bastani B. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis Report of a new case with literature review.Am J Kidney Dis. 2005; 46: 754-759Abstract Full Text Full Text PDF PubMed Scopus (140) Google Scholar herein), a careful hypercoagulation workup should precede any surgery, and appropriate precautions should be taken to avoid thrombotic loss of the new renal graft. For those who are unacceptable renal transplant candidates, additional therapeutic options have been described, but relatively few have been well documented. Perhaps the best-documented therapy to date is extracorporeal photopheresis. Extracorporeal photopheresis has proved beneficial in 3 patients in Europe.19Gilliet M. Cozzio A. Burg G. Nestle F.O. Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis.Br J Dermatol. 2005; 152: 531-536Crossref PubMed Scopus (116) Google Scholar These patients, all of whom had been stricken with NFD for less than 1 year, showed measurable and sustained improvement. Unfortunately, extracorporeal photopheresis therapy was discontinued in 1 of these patients because of insurance issues. In the United States, insurance coverage for extracorporeal photopheresis also continues to be difficult to procure for patients with NFD, but occasional trials of therapy can be justified on the basis of its resemblance to systemic sclerosis. As with systemic sclerosis (and other primary fibrosing processes), the underlying trigger has not yet been identified. Although it is clear that NFD/NSF does not seem capable of developing in patients with normal renal function, why are only a select few stricken? I do not know the answer to this question, but a systematic investigation is underway that will begin to address some of the suspects that have been raised, including high-dose erythropoietin,9Leboit P.E. What nephrogenic fibrosing dermopathy might be.Arch Dermatol. 2003; 139: 928-930Crossref PubMed Scopus (100) Google Scholar selective serotonin reuptake inhibitors, and lack of treatment with angiotensin-converting enzyme inhibitors.20Fazeli A. Lio P.A. Liu V. Nephrogenic fibrosing dermopathy Are ACE inhibitors the missing link?.Arch Dermatol. 2004; 140 (letter): 1401Crossref PubMed Google Scholar However, logic suggests that a single agent probably is not to blame. I remain optimistic that the culprits will be found and that we will all learn something new about fibrosis and wound healing in the process. Because the investigation of all aspects of NFD/NSF is still being pursued, all cases should be reported to the registry (http://www.icnfdr.org). The registry Web site is a regularly updated synopsis of the disease process and serves as the heart of the NFD/NSF research effort worldwide. Treatment experiences (both negative and positive) are especially helpful in the construction of future therapeutic trials. Nephrogenic Fibrosing Dermopathy/Nephrogenic Systemic Fibrosis: Report of a New Case With Literature ReviewAmerican Journal of Kidney DiseasesVol. 46Issue 4PreviewNephrogenic fibrosing dermopathy (NFD) is a fibrosing condition of the skin that is being described increasingly in patients with renal diseases, many of whom are on dialysis therapy or have undergone renal transplantation. Its etiopathology is unknown, and no standard therapy currently exists. We describe a patient with NFD for whom histopathologic studies indicated that the fibrotic process affected subcutaneous tissue, striated muscles, diaphragm, pleura, pericardium, great vessels of the heart, left ventricle and septum, and tunica albuginea in addition to the dermis. Full-Text PDF" @default.
• W2018786235 created "2016-06-24" @default.
• W2018786235 creator A5084954424 @default.
• W2018786235 date "2005-10-01" @default.
• W2018786235 modified "2023-10-04" @default.
• W2018786235 title "Nephrogenic Systemic Fibrosis: The Nosological and Conceptual Evolution of Nephrogenic Fibrosing Dermopathy" @default.
• W2018786235 cites W1970823600 @default.
• W2018786235 cites W1971497411 @default.
• W2018786235 cites W1974990423 @default.
• W2018786235 cites W1977058777 @default.
• W2018786235 cites W1990984281 @default.
• W2018786235 cites W1996623533 @default.
• W2018786235 cites W2004635611 @default.
• W2018786235 cites W2014259665 @default.
• W2018786235 cites W2014343076 @default.
• W2018786235 cites W2033907317 @default.
• W2018786235 cites W2034909082 @default.
• W2018786235 cites W2037282203 @default.
• W2018786235 cites W2042633155 @default.
• W2018786235 cites W2045780087 @default.
• W2018786235 cites W2071705959 @default.
• W2018786235 cites W2133988522 @default.
• W2018786235 cites W2143340697 @default.
• W2018786235 doi "https://doi.org/10.1053/j.ajkd.2005.08.008" @default.
• W2018786235 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16183434" @default.
• W2018786235 hasPublicationYear "2005" @default.
• W2018786235 type Work @default.
• W2018786235 sameAs 2018786235 @default.
• W2018786235 citedByCount "93" @default.
• W2018786235 countsByYear W20187862352012 @default.
• W2018786235 countsByYear W20187862352013 @default.
• W2018786235 countsByYear W20187862352014 @default.
• W2018786235 countsByYear W20187862352015 @default.
• W2018786235 countsByYear W20187862352016 @default.
• W2018786235 countsByYear W20187862352017 @default.
• W2018786235 countsByYear W20187862352018 @default.
• W2018786235 countsByYear W20187862352020 @default.
• W2018786235 countsByYear W20187862352022 @default.
• W2018786235 crossrefType "journal-article" @default.
• W2018786235 hasAuthorship W2018786235A5084954424 @default.
• W2018786235 hasBestOaLocation W20187862351 @default.
• W2018786235 hasConcept C126322002 @default.
• W2018786235 hasConcept C142724271 @default.
• W2018786235 hasConcept C2778653478 @default.
• W2018786235 hasConcept C2780559512 @default.
• W2018786235 hasConcept C2781027423 @default.
• W2018786235 hasConcept C71924100 @default.
• W2018786235 hasConceptScore W2018786235C126322002 @default.
• W2018786235 hasConceptScore W2018786235C142724271 @default.
• W2018786235 hasConceptScore W2018786235C2778653478 @default.
• W2018786235 hasConceptScore W2018786235C2780559512 @default.
• W2018786235 hasConceptScore W2018786235C2781027423 @default.
• W2018786235 hasConceptScore W2018786235C71924100 @default.
• W2018786235 hasIssue "4" @default.
• W2018786235 hasLocation W20187862351 @default.
• W2018786235 hasLocation W20187862352 @default.
• W2018786235 hasOpenAccess W2018786235 @default.
• W2018786235 hasPrimaryLocation W20187862351 @default.
• W2018786235 hasRelatedWork W2071182757 @default.
• W2018786235 hasRelatedWork W2073177925 @default.
• W2018786235 hasRelatedWork W2097614368 @default.
• W2018786235 hasRelatedWork W2104738562 @default.
• W2018786235 hasRelatedWork W2135415672 @default.
• W2018786235 hasRelatedWork W2369718642 @default.
• W2018786235 hasRelatedWork W2413522784 @default.
• W2018786235 hasRelatedWork W2767418652 @default.
• W2018786235 hasRelatedWork W2118652395 @default.
• W2018786235 hasRelatedWork W2185536823 @default.
• W2018786235 hasVolume "46" @default.
• W2018786235 isParatext "false" @default.
• W2018786235 isRetracted "false" @default.
• W2018786235 magId "2018786235" @default.
• W2018786235 workType "article" @default.